Μαιευτήρας - Χειρουργός - Γυναικολόγος

Ενδομήτριο

1. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia.
   Agorastos T, Vaitsi V, Paschopoulos M, Vakiani A, Zournatzi-Koiou V, Saravelos H, Kostopoulou E, Constantinidis T, Dinas K, Vavilis D, Lolis D, Bontis J.
   Maturitas. 2004 Jun 15;48(2):125-32.
2. Endometrial protein PP14 and CA-125 in recurrent miscarriage patients; correlation with pregnancy outcome.
   Dalton CF, Laird SM, Estdale SE, Saravelos HG, Li TC.
   Hum Reprod. 1998 Nov;13(11):3197-202.
3. Papillary metaplasia and decidualisation of the endometrium in a woman receiving tamoxifen and megoestrol acetate.
   Miliaras D, Saravelos H, Miliaras S, Lagos S.
   J Obstet Gynaecol. 1997 May;17(3):309-10.
4. The production of tumour necrosis factor alpha (TNF-alpha) by human endometrial cells in culture.
   Laird SM, Tuckerman EM, Saravelos H, Li TC.
   Hum Reprod. 1996 Jun;11(6):1318-23.
5. The measurement of CA 125 and placental protein 14 in uterine flushings in women with recurrent miscarriage; relation to endometrial morphology.
   Dalton CF, Laird SM, Serle E, Saravelos H, Warren MA, Li TC, Bolton AE.
   Hum Reprod. 1995 Oct;10(10):2680-4.
6. MUC1 in secretory phase endometrium: expression in precisely dated biopsies and flushings from normal and recurrent miscarriage patients.
   Hey NA, Li TC, Devine PL, Graham RA, Saravelos H, Aplin JD.
   Hum Reprod. 1995 Oct;10(10):2655-62.
7. Morphology of the human endometrium in the peri-implantation period.
   Li TC, Warren MA, Hill CJ, Saravelos H.
   Ann N Y Acad Sci. 1994 Sep 30;734:169-84.